Clinical Immunology Communications最新文献_第5页

Endogenous antibody response to SARS-CoV-2 in patients who received monoclonal antibodies against COVID-19: A systematic review 接受COVID-19单克隆抗体的患者对SARS-CoV-2的内源性抗体反应:一项系统综述

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.08.003

Andrea Lombardi , Cecilia Azzarà , Giulia Renisi , Giulia Viero , Andrea Gori , Alessandra Bandera

引用次数: 1

Differential peripheral blood mononuclear cell reactivity against SARS-CoV-2 proteins in naïve and previously infected subjects following COVID-19 vaccination naïve和先前感染的受试者接种COVID-19疫苗后外周血单个核细胞对SARS-CoV-2蛋白的反应性差异

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.11.004

Elizabete Cristina Iseke Bispo , Amandda Évelin Silva-Carvalho , Marielly Reis Resende Sousa , Francisco de Assis Rocha Neves , Juliana Lott Carvalho , Enrique Roberto Arganaraz , Felipe Saldanha-Araujo

{"title":"Differential peripheral blood mononuclear cell reactivity against SARS-CoV-2 proteins in naïve and previously infected subjects following COVID-19 vaccination","authors":"Elizabete Cristina Iseke Bispo , Amandda Évelin Silva-Carvalho , Marielly Reis Resende Sousa , Francisco de Assis Rocha Neves , Juliana Lott Carvalho , Enrique Roberto Arganaraz , Felipe Saldanha-Araujo","doi":"10.1016/j.clicom.2022.11.004","DOIUrl":"10.1016/j.clicom.2022.11.004","url":null,"abstract":"<div><p>The decline in vaccine efficacy and the risk of reinfection by SARS-CoV-2 make new studies important to better characterize the immune response against the virus and its components. Here, we investigated the pattern of activation of T-cells and the expression of inflammatory factors by PBMCs obtained from naïve and previously infected subjects following COVID-19 vaccination, after PBMCs stimulation with S1, RBD, and N-RBD SARS-CoV-2 proteins. PBMCs showed low levels of <em>ACE2</em> and <em>TMPRSS2</em> transcripts, which were not modulated by the exposure of these cells to SARS-CoV-2 proteins. Compared to S1 and RBD, N-RBD stimulation showed a greater ability to stimulate T-cell reactivity, according to CD25 and CD69 markers. Interestingly, T-cell reactivity was more pronounced in vaccinated subjects with prior SARS-CoV-2 infection than in vaccinated donors who never had been diagnosed with COVID-19. Finally, N-RBD stimulation promoted greater expression of IL-6 and IFN-γ in PBMCs, which reinforces the greater immunogenic potential of this protein in the vaccinated subjects. These data suggest that PBMCs from previously infected and vaccinated subjects are more reactive than those derived from just vaccinated donors. Moreover, the N-RBD together viral proteins showed a greater stimulatory capacity than S1 and RBD viral proteins.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000300/pdfft?md5=01850fb2c16cec9ac69238b08d2f7f61&pid=1-s2.0-S2772613422000300-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77932107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG 抗sars - cov -2 IgG水平流式定量检测装置的性能评价

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.09.001

J.S. Moore , L.J. Robertson , R. Price , G. Curry , J. Farnan , A. Black , M.A. Nesbit , J.A. McLaughlin , T. Moore

{"title":"Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG","authors":"J.S. Moore , L.J. Robertson , R. Price , G. Curry , J. Farnan , A. Black , M.A. Nesbit , J.A. McLaughlin , T. Moore","doi":"10.1016/j.clicom.2022.09.001","DOIUrl":"10.1016/j.clicom.2022.09.001","url":null,"abstract":"<div><p>Introduction: The AbC-19™ lateral flow immunoassay (LFIA) performance was evaluated on plasma samples from a SARS-CoV-2 vaccination cohort, WHO international standards for anti-SARS-CoV-2 IgG (human), individuals ≥2 weeks from infection of RT-PCR confirmed SARS-CoV-2 genetic variants, as well as microorganism serology.</p><p>Methods: Pre-vaccination to three weeks post-booster samples were collected from a cohort of 111 patients (including clinically extremely vulnerable patients) from Northern Ireland. All patients received Oxford-AstraZeneca COVID-19 vaccination for the first and second dose, and Pfizer-BioNTech for the third (first booster). WHO international standards, 15 samples from 2 variants of concern (Delta and Omicron) and cross-reactivity with plasma samples from other microorganism infections were also assessed on AbC-19™.</p><p>Results: All 80 (100%) participants sampled post-booster had high positive IgG responses, compared to 38/95 (40%) participants at 6 months post-first vaccination. WHO standard results correlated with information from corresponding biological data sheets, and antibodies to all genetic variants were detected by LFIA. No cross-reactivity was found with exception of one (of five) Dengue virus samples.</p><p>Conclusion: These findings suggest BNT162b2 booster vaccination enhanced humoral immunity to SARS-CoV-2 from pre-booster levels, and that this antibody response was detectable by the LFIA. In combination with cross-reactivity, standards and genetic variant results would suggest LFIA may be a cost-effective measure to assess SARS-CoV-2 antibody status.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277261342200021X/pdfft?md5=573dcfdb4bafa05ccf57518ff31f08ca&pid=1-s2.0-S277261342200021X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90041150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE) 系统性红斑狼疮(SLE)患者全mRNA COVID-19疫苗接种后SARS-CoV-2感染的评价

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.03.002

Anderson Anuforo , Michael Sandhu , Jianghong Yu , Andras Perl

{"title":"Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE)","authors":"Anderson Anuforo , Michael Sandhu , Jianghong Yu , Andras Perl","doi":"10.1016/j.clicom.2022.03.002","DOIUrl":"10.1016/j.clicom.2022.03.002","url":null,"abstract":"<div><p>The 2019 Coronavirus disease (COVID-19) vaccine is a major weapon in the fight against the severe acute respiratory syndrome brought about by coronavirus 2 (SARS-CoV-2). The vaccine significantly reduces the risk and severity of infection by SARS-CoV-2. Patients with systemic lupus erythematosus (SLE) need protection from vaccine-preventable diseases including COVID-19. SLE patients have higher rates of severe infections due to immunosuppressive therapies and multiple immunologic defects – both of which are capable of blunting the immune responses after vaccination. In the management of COVID-19, recommendations have been developed to guide adjustments and/or continuation of immunosuppressive therapies for an effective immune response following vaccination with mRNA-based or viral vector-delivered vaccines. Monoclonal antibodies have also become available since December 2021. Here we present three cases of SLE patients who contracted COVID-19 after vaccination. One was managed in ambulatory settings and two required inpatient hospital admission.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000087/pdfft?md5=1f91cdb759b25fb7b7849308c5532a86&pid=1-s2.0-S2772613422000087-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77497960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis mepolizumab治疗嗜酸性肉芽肿合并多血管炎的临床疗效和安全性

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.01.002

Giuseppe A. Ramirez , Adriana Cariddi , Silvia Noviello , Corrado Campochiaro , Valentina Canti , Luca Moroni , Mona-Rita Yacoub , Elena M. Baldissera , Enrica P. Bozzolo , Lorenzo Dagna

{"title":"Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis","authors":"Giuseppe A. Ramirez , Adriana Cariddi , Silvia Noviello , Corrado Campochiaro , Valentina Canti , Luca Moroni , Mona-Rita Yacoub , Elena M. Baldissera , Enrica P. Bozzolo , Lorenzo Dagna","doi":"10.1016/j.clicom.2022.01.002","DOIUrl":"10.1016/j.clicom.2022.01.002","url":null,"abstract":"<div><p>Little is known about the efficacy and safety of the anti-interleukin 5 monoclonal antibody mepolizumab (MPZ) in patients with eosinophilic granulomatosis with polyangiitis (EGPA) in real-life. We thus evaluated disease activity, damage and disease-related complications in 14 patients with EGPA receiving MPZ for refractory disease for a median time of 16 months in comparison with up to five years before MPZ start. Asthma exacerbation rates, the Birmingham Vasculitis Activity Score and corticosteroid dosage decreased during MPZ (<em>p</em> < 0.001, <em>p</em> < 0.001 and <em>p</em> = 0.001, respectively). Five patients could discontinue prednisone. Infection rates were higher during MPZ (<em>p</em> < 10<sup>–6</sup>), but no rises in hospitalizations, asthma exacerbations or damage accrual were observed. Real-life data confirm the effectiveness of MPZ in refractory EGPA with active asthma. Higher infections rates are in line with other studies and might be due to relative overreporting secondary to increased visit frequency, although a pharmacological effect could not be ruled out.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000026/pdfft?md5=75f1aaeb7ec37ac86b981dbe92716b4d&pid=1-s2.0-S2772613422000026-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83830340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Continuous increase of immunoglobulin therapy in Iceland 冰岛免疫球蛋白治疗持续增加

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.06.001

Valgeir Steinn Runólfsson , Björn Rúnar Lúdvíksson , Rannveig Einarsdóttir , Þórunn Óskarsdóttir , Valtýr Thors , Ásgeir Haraldsson

{"title":"Continuous increase of immunoglobulin therapy in Iceland","authors":"Valgeir Steinn Runólfsson , Björn Rúnar Lúdvíksson , Rannveig Einarsdóttir , Þórunn Óskarsdóttir , Valtýr Thors , Ásgeir Haraldsson","doi":"10.1016/j.clicom.2022.06.001","DOIUrl":"10.1016/j.clicom.2022.06.001","url":null,"abstract":"<div><h3>Background</h3><p>The use of immunoglobulin treatment has been increasing for various indications. The objective of this study was to evaluate clinical use of immunoglobulin therapy in Iceland, estimate off-label usage and describe possible changes in this treatment option.</p></div><div><h3>Methods</h3><p>All prescriptions for intravenous or subcutaneous immunoglobulin treatment require authorisation from Landspitali University Hospital. Patient information is registered and was retrieved for the period 2010 to 2019.</p></div><div><h3>Results</h3><p>A total of 921 patients received immunoglobulin treatment in the study period, intravenous therapy was given in 895 (97.2%) of the cases. Registered indications were 667, off-label indications were 245 and uncertain were nine. The total annual number of patients receiving immunoglobulin treatment increased from 87 in 2010 to 392 in 2019. The increase in immunoglobulin usage was both for registered and off-label indications, 61 to 309 and 26 to 83, respectively.</p></div><div><h3>Conclusion</h3><p>Continually increasing demand and global shortage dictates careful consideration of indications before initiating or continuing treatment with immunoglobulins.</p></div><div><h3>Key Message</h3><p>With global shortage of immunoglobulins, careful consideration and patient selection is important.</p></div><div><h3>Capsule Summary</h3><p>Increasing immunoglobulin usage improves treatment for many patients. However, immunoglobulins are a limited resource and prudent use is imperative.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000166/pdfft?md5=d2e9a1c98031d58c62b43968b92b97b0&pid=1-s2.0-S2772613422000166-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76214660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Daily oral vitamin D3 without concomitant therapy in the management of psoriasis: A case series 每日口服维生素D3不伴随治疗牛皮癣的管理:一个病例系列

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.01.001

Renu Mahtani , Pradeep M.K. Nair

引用次数: 0

Her2 expression can predict the survival of patients with salivary duct carcinoma Her2表达可预测涎腺导管癌患者的生存

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.09.004

Toshiaki Kawano, Takashi Hirano, Sonoka Takakura, Kazue Ito, Masashi Urabe, Kaori Tateyama, Masashi Suzuki

{"title":"Her2 expression can predict the survival of patients with salivary duct carcinoma","authors":"Toshiaki Kawano, Takashi Hirano, Sonoka Takakura, Kazue Ito, Masashi Urabe, Kaori Tateyama, Masashi Suzuki","doi":"10.1016/j.clicom.2022.09.004","DOIUrl":"10.1016/j.clicom.2022.09.004","url":null,"abstract":"<div><p>Salivary duct carcinoma (SDC) is a high-grade malignant tumor that mainly develops in the salivary glands, and SDC patients have a 5-year survival rate of less than 50%. Thirteen SDC patients (11 male and 2 female, average age 67.2 years) with primary salivary gland carcinoma who received primary treatment in our department from 2005 to 2016.</p><p>Although markers such as androgen receptors and gross cystic disease fluid protein-15 are effective in diagnosing SDC, there are no effective tumor-specific markers for prognosis prediction. Therefore, we investigated the expressions of human epidermal growth factor receptor 2 (Her2), Ki-67, EGFR, p16, P53 and PD-L1, and examined their prognostic effect.</p><p>Multivariate analysis showed that high Her2 expression was an exacerbating prognostic factor. In the future, the use of molecular-targeted drugs and immune checkpoint inhibitors for salivary gland malignancies may become more frequent. Her2 expression could be used as a predictor of prognosis.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000245/pdfft?md5=55a1cecc8e62cd16180601ad19dfd669&pid=1-s2.0-S2772613422000245-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78832159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influenza A and influenza B antibody determination in an Austrian cohort 奥地利队列甲型流感和乙型流感抗体测定

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.09.002

Elisabeth Mara, Johannes Gratzer, Tobias Mader, Thomas Pekar

引用次数: 0

Early-onset Crohn's disease, IgA nephropathy, and hemophagocytic lymphohistiocytosis in a patient with IL-10 receptor deficiency IL-10受体缺乏患者的早发性克罗恩病、IgA肾病和噬血细胞性淋巴组织细胞增多症

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.09.003

Amer Khojah , Lauren Gunderman , Ameera Bukhari , Madeline Schutt , Valeria Cohran

{"title":"Early-onset Crohn's disease, IgA nephropathy, and hemophagocytic lymphohistiocytosis in a patient with IL-10 receptor deficiency","authors":"Amer Khojah , Lauren Gunderman , Ameera Bukhari , Madeline Schutt , Valeria Cohran","doi":"10.1016/j.clicom.2022.09.003","DOIUrl":"https://doi.org/10.1016/j.clicom.2022.09.003","url":null,"abstract":"<div><p>IL-10 receptor (IL-10R) deficiency is a rare immune dysregulation disorder that is characterized by early-onset and life-threatening inflammatory bowel disease (IBD). Activation of the IL-10R inhibits the release of pro-inflammatory cytokines resulting in decreased inflammation. Herein, we present a case of novel homozygous IL-10RA mutation (c.243T>A; p.Y81*) resulting in early-onset Crohn's disease and failure to thrive who was treated with anakinra (IL-1 blocker). His disease course was complicated with IgA nephropathy while anakinra was held for the treatment of osteomyelitis and improved when anakinra was restarted. A year later, he developed inflammatory brain disease and Hemophagocytic Lymphohistiocytosis (HLH), which was treated with high dose steroid and hematopoietic stem cell transplant (HSCT). This case highlights IgA nephropathy, CNS autoinflammation, and HLH as possible extraintestinal manifestations of IL-10 receptor deficiency, especially in the setting of delayed stem cell transplantation.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000233/pdfft?md5=c6b5410ddc01651e12c137683c449954&pid=1-s2.0-S2772613422000233-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137157042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0